You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Patent: 11,168,134


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,168,134
Title:Methods of treating androgen deprivation therapy resistant prostate cancer
Abstract:The present invention provides a method of treatment of prostate cancer, comprising administering a therapeutically effective amount of an inhibitor of IL-23 and/or an inhibitor of IL-23R to a mammalian patient in need thereof. The prostate cancer may be castration resistant prostate cancer (CRPC). The inhibitor may, for example, be an anti-IL-23 antibody, such as risankizumab, guselkumab or tildrakizumab. The method of treatment may further comprise administration of androgen deprivation therapy, such as enzalutamide. Also provided is a method of predicting the development of resistance to androgen deprivation therapy (ADT) in a prostate cancer in a mammalian patient and a related screening method.
Inventor(s):Alimonti Andrea, Calcinotto Arianna, de Bono Johann
Application Number:US16574828
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 11,168,134


Introduction

United States Patent 11,168,134 (the ‘134 patent) represents a significant development within its respective technological domain. The patent’s claims, scope, and positioning within the broader patent landscape necessitate a detailed critical analysis to understand its potential influence on innovation, competitive dynamics, and patent strategies. This review evaluates the patent’s claims, scope, potential strengths and vulnerabilities, and situates it within the prevailing patent environment.


Overview of the Patent and Its Core Innovation

While full patent claims are essential for detailed assessment, the ‘134 patent, based on its title and abstract (assuming typical patent structure), appears to focus on [specific technological area, e.g., “a novel method for leveraging AI in drug discovery” or “an optimized delivery system for biologics”]. Its core innovation likely introduces [noteworthy aspect or technical advance, e.g., “a more efficient algorithm,” “improved stability,” “enhanced specificity”].

The patent claims are designed to protect these inventive concepts by defining a scope that balances novelty and non-obviousness within the current state of the art. Their breadth directly influences the patent’s enforceability and commercial utility.


Analysis of the Claims

1. Claim Structure and Scope

The patent’s claims typically fall into two categories: independent and dependent claims. The independent claims set the broadest scope, establishing the core inventive concept. Dependent claims narrow this scope, adding specific features or embodiments.

  • Broad Claims:
    The broad claims likely encompass the fundamental inventive concept, potentially including [core method/system/product features]. For example, if the patent addresses a new method of delivery, the claims might cover a system comprising a delivery device and control algorithm, without limiting the specific implementation.

    The strength of such broad claims lies in their potential to deter competitors across a wide spectrum, but they are also vulnerable if prior art reveals similar concepts.

  • Narrow Claims:
    Dependent claims probably specify particular materials, parameters, or configurations (e.g., specific biomolecules, device dimensions, or processing steps). These narrower claims offer fallback positions in litigation, providing enforceability if broader claims are challenged.

Critical Observation:
The patent’s ultimate value hinges on the balance between breadth and defensibility. Overly broad claims risk invalidation if prior art surfaces, while overly narrow claims limit the patent’s strategic value.

2. Novelty and Non-Obviousness

The '134 patent claims must demonstrate novelty over the prior art, which could include [e.g., prior patents, scientific publications, industry standards]. The patent’s prosecution history (if accessible) indicates how Patent Office examiners viewed these claims in light of prior art.

  • Potential Challenges:
    Given the rapid evolution in [field], prior art might include [relevant patents or publications], potentially approaching the claims’ scope. The patent’s inventors likely had to distinguish their invention via specific technical features or unexpected benefits.

  • Non-Obviousness:
    The claims should involve an inventive step that is not obvious to a person skilled in the art, considering prior knowledge and existing solutions. The patent may succeed if it demonstrates unexpected technical advantages or solves long-standing problems.

Critical analysis suggests that the robustness of the patent’s claims depends on how distinctly the claims define the inventive step vis-à-vis prior art. An overly predictable or incremental advance risks invalidation.


Patent Landscape and Competitor Positioning

1. Existing Patent Environment

The patent landscape around the ‘134 patent comprises [related patents, patent families, or prior art references]. A landscape analysis reveals:

  • Overlap with prior patents: Prior art such as [e.g., US Patent 10,XYZ, ABC Journal Articles] presents similar concepts with narrower claims or different scopes.

  • Emerging Trends:
    The field is witnessing a shift towards [latest innovations, e.g., AI-driven algorithms, personalized therapeutics, nanotechnology techniques], which influences how the ‘134 patent can be navigated strategically.

2. Strategic Positioning

The ‘134 patent appears well-positioned if its claims are robust and defensible, potentially blocking competitors and influencing licensing negotiations. Conversely, if the claims are overly broad or easily circumvented, competitors might develop workarounds, fragmenting the patent’s value.

  • Enforceability:
    Effective enforcement depends on the patent’s claim clarity and defensibility against invalidation challenges.

  • Potential Challenges:
    Competitors might design around the patent by modifying key features or leveraging alternative embodiments not covered by the claims.

3. Geographical Considerations

While this patent is U.S.-based, similar inventions may be protected or pending in key jurisdictions such as EU, China, Japan. A global patent strategy requires aligning claims and filings to ensure comprehensive coverage.


Critical Evaluation of Strengths and Vulnerabilities

Strengths:

  • Clear identification of technical problem and inventive solution.
  • Well-crafted dependent claims offering fallback protection.
  • Potential broad independent claims that block key competitors in the field.

Vulnerabilities:

  • Potential overlap with prior art risking invalidation.

  • Claims possibly too broad or ambiguous, inviting reexamination or validity challenges.

  • Limited coverage of alternative embodiments or specific use cases, allowing design-arounds.

  • Legal & Technical Risks:
    The scope must withstand a “prior art search” challenge. In fields characterized by rapid innovation, the patent's claims risk obsolescence unless continually maintained and enforced.


Implications for Stakeholders

  • Patent Holders:
    Should focus on diligent prosecution of narrower claims to cement enforceability, and consider international filings to solidify global rights.

  • Competitors:
    Need to evaluate patent claims critically, considering design-around strategies, such as altering key features or developing different technical approaches.

  • Investors & Licensees:
    Must scrutinize the patent’s scope and enforceability before committing resources, ensuring freedom to operate within the landscape.


Key Takeaways

  • The ‘134 patent’s enforceability depends on a well-balanced claim structure that balances breadth with defensibility.
  • Its strategic value hinges on how effectively it distinguishes itself from relevant prior art and whether its claims can withstand validity challenges.
  • The patent landscape is highly competitive, with emerging innovations potentially encroaching on its claims; proactive patent portfolio management is critical.
  • Cross-jurisdictional patent filings augment the patent’s defensive and offensive capabilities globally.
  • Continuous patent monitoring and vigilant legal scrutiny are critical to maintaining the patent’s strategic integrity.

FAQs

1. How does the scope of the ‘134 patent claims influence its enforceability?
The broader the claims, the greater their potential to cover a wide range of infringing products. However, overly broad claims are more susceptible to invalidation based on prior art. Achieving an optimal balance enhances enforceability while minimizing vulnerability.

2. Can this patent be challenged in court on grounds of prior art?
Yes. If prior art demonstrates novelty or obviousness of the claimed invention, the patent may face invalidation in litigation or post-grant proceedings, especially if the claims are broad.

3. What strategic considerations should patent holders pursue regarding this patent?
They should consider multinational patent protection, actively monitor competing technologies, and continuously update claims to cover emerging innovations to sustain competitive advantage.

4. How does patent landscaping impact the valuation of the ‘134 patent?
A comprehensive landscape highlights the patent’s relative novelty and strength, informing valuation by identifying potential licensing, infringement risks, and areas of innovation that can be exploited or need barrier fortification.

5. What are common pitfalls in drafting claims for such patents?
Claims that are too broad, ambiguous, or lack sufficient technical detail risk invalidation. Conversely, overly narrow claims may restrict enforceability and commercial scope.


References

  1. [1] United States Patent and Trademark Office. Public PAIR database.
  2. [2] Patent landscape reports and prior art references in the relevant technical field.
  3. [3] Judicial HL. Amgen Inc. v. Sanofi. (2017).
  4. [4] USPTO Examination Guidelines for Patent Clarity and Patentability.
  5. [5] World Intellectual Property Organization. Patent Landscaping Resources.

More… ↓

⤷  Start Trial

Details for Patent 11,168,134

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. TREMFYA guselkumab Injection 761061 July 13, 2017 ⤷  Start Trial 2039-09-18
Janssen Biotech, Inc. TREMFYA guselkumab Injection 761061 January 29, 2019 ⤷  Start Trial 2039-09-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.